

Felix™ Registration Achieved in Turkey, Commercial Sales Commence

Highlights

- Turkey registration unlocks commercial sales of Felix™ under the International Technical Legacy (ITL) agreement, with an initial sale of 100 cartridges and two consoles completed.
- Turkey is a large, established assisted-reproduction market, with 165 ART centres identified in a 2024 national study.
- Local distributor training completed by Memphasys team supporting clinic engagement, product demonstrations and further sales growth.

Memphasys Limited (ASX: MEM) ("Memphasys" or "the Company") is pleased to advise that the Felix™ System has received the required product registration in Turkey, enabling ITL to commence commercial sales of the Felix™ cartridge and console into the Turkish market through its local distribution network. The registration is recorded on Turkey's national Product Tracking System (ÜTS)¹.

Commercial Roll-out Under the ITL Agreement

Turkey was added to the ITL distribution territory following CE Mark approval and the expansion of the agreement in September 2025.² The first commercial sale in Turkey has now been completed, comprising 100 Felix™ cartridges and two consoles. This provides an installed platform from which the local distributor can undertake clinic demonstrations, education and customer conversion activities and the Company expects additional orders as IVF clinics are now engaged by commercial partners.

Memphasys has already completed hands-on product training with ITL's in-country distribution partner. This early training is intended to equip the local team to introduce Felix™ to IVF clinics and to support the technical and workflow discussions that are central to adoption of new laboratory technologies.

Turkish Market Opportunity

Turkey has a large and established assisted-reproduction sector. A peer-reviewed national study published in 2024 identified 165 ART centres operating in the country. Turkey is estimated to undertake approximately 75,000 assisted reproductive technology (ART) treatment cycles annually.³ The Company and its local distribution partner will now expand market-development activity in Turkey through clinic engagement, product demonstrations and further training. Memphasys expects these activities to support additional cartridge and

¹ Turkey Product Tracking System (ÜTS) product registration records for FCAR001 and FCON001, accessed 31 August 2026.

² Refer ASX announcements dated 18 September 2025 and 27 May 2026

³ Gürkan T, Salman C, Demirel A, *Dynamic view of assisted reproduction in Turkey from 1996 to 2020*, **Reproductive BioMedicine Online**, 2022.

console sales over coming quarters; however, the timing and value of future orders will depend on clinic adoption and purchasing decisions.

A/Prof Hassan Bakos, Memphasys Director of Clinical Partnerships and Growth, commented: “Regulatory registration in Turkey is an important commercial enabler for Felix™ under our ITL agreement. The initial sale and distributor training give us a practical starting point in a large, established IVF market. As local marketing and clinical training activities expand, we expect to see further interest from IVF clinics and opportunities to build recurring cartridge demand.”

ITL Agreement

ITL is Memphasys' exclusive commercial partner for the Middle East and North Africa under a five-year agreement. Before the Turkish order, ITL had placed orders for 1,800 Felix™ cartridges - 72% of its 2,500-cartridge territory-wide minimum annual purchase commitment - in less than two quarters.⁴

This announcement has been authorised for release by the Board of Memphasys Limited.

ENDS

For further information, please contact:

Colin Jacoby
Chapter One Advisors
Tel: +61 439 980 359
E: cjacoby@chapteroneadvisors.com.au

About Memphasys

Memphasys Limited (ASX: MEM) is an Australian-based reproductive biotechnology company commercialising the Felix™ System, a patented bio-separation technology that isolates the most viable sperm cells for human assisted reproduction.

By combining electrophoresis and size-exclusion membranes, Felix™ delivers a fast, gentle and standardised sperm-selection process that enhances sperm quality and reduces laboratory time. The system replaces traditional centrifugation, which can cause cellular stress and DNA damage, offering clinicians a superior, repeatable alternative.

Memphasys' commercial strategy focuses on building contracted sales through direct and distribution-led channels, scaling production to improve margins, and establishing Felix™ as a new global standard in sperm preparation for ART procedures.

Website: www.memphasys.com

The Felix™ System is a registered trademark of Memphasys Limited. All rights reserved.

⁴ Refer ASX announcement dated 27 May 2026. The 1,800 cartridges represented 72% of ITL's 2,500-cartridge annual minimum commitment prior to the Turkish order.

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These statements are based on Memphasys' current expectations, estimates and projections, and are subject to risks and uncertainties that could cause actual results to differ materially. Forward-looking statements are not guarantees of future performance. Memphasys cautions shareholders and prospective shareholders not to place undue reliance on these statements, which speak only as at the date of this announcement.